Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
| dc.contributor.author | Shey, Muki Shehu. | |
| dc.contributor.author | Kongnyuy, Eugene J. | |
| dc.contributor.author | Alobwede, Samuel M. | |
| dc.contributor.author | Wiysonge, Charles Shey. | |
| dc.date.accessioned | 2013-12-09T07:21:32Z | |
| dc.date.available | 2013-12-09T07:21:32Z | |
| dc.date.created | 2013 | |
| dc.date.issued | 2013 | |
| dc.description.abstract | The primary objective of this review was to evaluate the antiviral efficacy of co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection. The secondary objectives were to evaluate the safety and tolerability of the triple drug combination. We identified 15 potentially eligible studies, four of which met our inclusion criteria. Our findings indicate that co-formulated abacavirlamivudine-zidovudine remains a viable option for initiating antiretroviral therapy, especially in HIV-infected patients with pre-existing hyperlipidaemia and those who do not tolerate ritonavir. | en |
| dc.identifier.citation | Shey, M.S., Kongnyuy, E.J., Alobwede, S.M., Wiysonge, C.S. 2013. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS. Cochrane Database of Systematic Reviews (3) Art. No.: CD005481. | |
| dc.identifier.issn | 1469-493X | |
| dc.identifier.uri | http://dx.doi.org/10.1002/14651858.CD005481.pub3. | en |
| dc.identifier.uri | http://hdl.handle.net/10413/10180 | |
| dc.language.iso | en | en |
| dc.publisher | The Cochrane Collaboration. | en |
| dc.subject | HIV infections--Drug therapy. | en |
| dc.subject | Antiretroviral agents. | en |
| dc.subject.other | Combination antiretroviral therapy. | en |
| dc.subject.other | Triple drug combination. | en |
| dc.title | Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS. | en |
| dc.type | Peer reviewed journal article | en |